Hazel Hunt compensation by year
CORCEPT THERAPEUTICS Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $431,873 |
| Bonus | $243,000 |
| Stock awards | $0 |
| Option awards | $2,084,640 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $2,759,513 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CORCEPT THERAPEUTICS INC DEF 14A filed April 22, 2021, accession 0001628280-21-007363, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CORCEPT THERAPEUTICS INC filed document, accession 0001628280-21-007363. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 43,750 | — | $16.52 |
| Option | 81,250 | — | $11.35 |
| Option | 8,334 | — | $8.27 |
| Option | 35,834 | — | $15.82 |
| Option | 158,334 | — | $13.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CORCEPT THERAPEUTICS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
20 Form 4 lines since the FY2020 proxy (filed April 22, 2021)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-27 | Grant or award derivative | — | 140,000 | $0.00 | 140,000 |
| 2026-02-09 | Exercise or conversion | — | 150,000 | $3.88 | 333,405 |
| 2026-02-09 | Tax withholding | — | 77,968 | $41.31 | 255,437 |
| 2026-02-09 | Exercise or conversion derivative | — | 150,000 | $0.00 | 0 |
| 2025-02-28 | Grant or award derivative | — | 140,000 | $0.00 | 140,000 |
| 2025-02-11 | Exercise or conversion | — | 150,000 | $3.29 | 268,581 |
| 2025-02-11 | Exercise or conversion derivative | — | 150,000 | $0.00 | 0 |
| 2025-02-11 | Tax withholding | — | 85,176 | $68.11 | 183,405 |
The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CORCEPT THERAPEUTICS’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Joseph Belanoff | Chief Executive Officer and President (3) | $5,762,102 |
| Sean Maduck | Chief Commercial Officer (6) | $3,196,941 |
| Charles Robb | Chief Business Officer and Secretary (7) | $2,914,438 |
| Hazel Hunt · this page | Chief Scientific Officer (5) (6) | $2,759,513 |
| Andreas Grauer | Chief Medical Officer (4) | $2,063,274 |
The full CORCEPT THERAPEUTICS compensation record
free company briefThis page is one person within CORCEPT THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CORCEPT THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.